Gilead's Sovaldi--Courtesy of Gilead |
Individual payers aren't alone in balking at the $84,000 price for Gilead Sciences' ($GILD) new hepatitis C treatment Sovaldi. Now, the leading insurance trade group has joined the soloists, backing their complaints with its own. Report